Alison Abraham
Concepts (304)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 51 | 2024 | 2469 | 4.740 |
Why?
| Cognitive Dysfunction | 6 | 2023 | 284 | 2.800 |
Why?
| Sexual and Gender Minorities | 6 | 2021 | 138 | 2.510 |
Why?
| Retinal Vessels | 4 | 2022 | 50 | 2.310 |
Why?
| Renal Insufficiency, Chronic | 14 | 2024 | 486 | 1.890 |
Why?
| Dry Eye Syndromes | 5 | 2024 | 28 | 1.680 |
Why?
| Glomerular Filtration Rate | 19 | 2024 | 604 | 1.530 |
Why?
| Tomography, Optical Coherence | 3 | 2023 | 130 | 1.510 |
Why?
| Homosexuality, Male | 8 | 2021 | 170 | 1.430 |
Why?
| Viral Load | 10 | 2021 | 405 | 1.320 |
Why?
| Cognition Disorders | 2 | 2023 | 476 | 1.240 |
Why?
| Antiretroviral Therapy, Highly Active | 9 | 2018 | 256 | 1.220 |
Why?
| Vision Disorders | 4 | 2023 | 130 | 1.210 |
Why?
| Depression | 4 | 2020 | 1133 | 1.130 |
Why?
| Hearing Loss | 4 | 2023 | 183 | 1.100 |
Why?
| Bias | 4 | 2022 | 179 | 0.990 |
Why?
| Vitamin D Deficiency | 2 | 2017 | 158 | 0.980 |
Why?
| Anti-Retroviral Agents | 5 | 2018 | 207 | 0.960 |
Why?
| Atherosclerosis | 4 | 2022 | 341 | 0.950 |
Why?
| Anti-HIV Agents | 7 | 2018 | 666 | 0.940 |
Why?
| AIDS-Associated Nephropathy | 4 | 2017 | 7 | 0.930 |
Why?
| Hypertension | 6 | 2023 | 1056 | 0.910 |
Why?
| Masks | 1 | 2023 | 46 | 0.860 |
Why?
| Cohort Studies | 26 | 2023 | 4894 | 0.850 |
Why?
| Cognitive Aging | 1 | 2023 | 14 | 0.840 |
Why?
| Fluorescein Angiography | 2 | 2022 | 102 | 0.840 |
Why?
| Diabetes Mellitus | 5 | 2022 | 900 | 0.830 |
Why?
| Male | 59 | 2023 | 55554 | 0.810 |
Why?
| CD4 Lymphocyte Count | 11 | 2021 | 257 | 0.810 |
Why?
| Eye | 1 | 2023 | 98 | 0.800 |
Why?
| Cross-Sectional Studies | 19 | 2023 | 4405 | 0.770 |
Why?
| Aged | 26 | 2023 | 19061 | 0.760 |
Why?
| Visually Impaired Persons | 1 | 2020 | 6 | 0.710 |
Why?
| Humans | 87 | 2024 | 114623 | 0.710 |
Why?
| Middle Aged | 46 | 2021 | 26719 | 0.710 |
Why?
| Adult Survivors of Child Adverse Events | 1 | 2020 | 10 | 0.700 |
Why?
| Glaucoma | 1 | 2023 | 202 | 0.680 |
Why?
| Cognition | 4 | 2023 | 988 | 0.680 |
Why?
| Crime Victims | 1 | 2020 | 80 | 0.630 |
Why?
| Viremia | 2 | 2018 | 122 | 0.620 |
Why?
| Vitamin D | 2 | 2018 | 341 | 0.590 |
Why?
| Body Size | 1 | 2018 | 91 | 0.590 |
Why?
| Kidney | 12 | 2024 | 1188 | 0.590 |
Why?
| HIV | 6 | 2020 | 208 | 0.580 |
Why?
| Kidney Diseases | 4 | 2014 | 350 | 0.570 |
Why?
| Survivors | 1 | 2020 | 411 | 0.560 |
Why?
| Hepatitis C | 4 | 2023 | 219 | 0.530 |
Why?
| Risk Factors | 25 | 2024 | 8628 | 0.530 |
Why?
| Dementia | 1 | 2019 | 187 | 0.530 |
Why?
| Immunologic Factors | 1 | 2018 | 220 | 0.520 |
Why?
| Kidney Failure, Chronic | 3 | 2017 | 489 | 0.510 |
Why?
| Psychiatric Status Rating Scales | 1 | 2018 | 482 | 0.510 |
Why?
| Prospective Studies | 19 | 2022 | 6217 | 0.510 |
Why?
| Female | 48 | 2024 | 59466 | 0.510 |
Why?
| Microbiota | 1 | 2023 | 647 | 0.500 |
Why?
| Body Composition | 2 | 2018 | 590 | 0.490 |
Why?
| Aging | 3 | 2023 | 1618 | 0.480 |
Why?
| Depressive Disorder | 1 | 2018 | 332 | 0.480 |
Why?
| Biomarkers | 14 | 2024 | 3408 | 0.460 |
Why?
| Executive Function | 2 | 2023 | 379 | 0.460 |
Why?
| Adult | 44 | 2023 | 30528 | 0.450 |
Why?
| Attention | 1 | 2017 | 393 | 0.450 |
Why?
| Substance-Related Disorders | 1 | 2021 | 947 | 0.420 |
Why?
| Prevalence | 7 | 2022 | 2249 | 0.400 |
Why?
| Stress, Psychological | 1 | 2020 | 944 | 0.400 |
Why?
| Anemia | 1 | 2012 | 143 | 0.370 |
Why?
| United States | 18 | 2024 | 12176 | 0.360 |
Why?
| Longitudinal Studies | 6 | 2022 | 2387 | 0.360 |
Why?
| Comorbidity | 4 | 2021 | 1448 | 0.350 |
Why?
| Independent Living | 2 | 2022 | 84 | 0.340 |
Why?
| Creatinine | 9 | 2023 | 425 | 0.330 |
Why?
| Metabolomics | 3 | 2023 | 521 | 0.330 |
Why?
| Aged, 80 and over | 8 | 2023 | 6344 | 0.330 |
Why?
| Hospitals | 2 | 2023 | 581 | 0.320 |
Why?
| Neuropsychological Tests | 4 | 2022 | 927 | 0.310 |
Why?
| Bone Density | 2 | 2022 | 432 | 0.310 |
Why?
| Incidence | 9 | 2022 | 2311 | 0.270 |
Why?
| Sensitivity and Specificity | 3 | 2018 | 1691 | 0.250 |
Why?
| HIV-1 | 5 | 2017 | 768 | 0.250 |
Why?
| Iohexol | 2 | 2015 | 16 | 0.240 |
Why?
| Renal Insufficiency | 2 | 2017 | 137 | 0.240 |
Why?
| Kidney Function Tests | 4 | 2017 | 140 | 0.230 |
Why?
| Tears | 1 | 2023 | 14 | 0.220 |
Why?
| Plaque, Atherosclerotic | 1 | 2023 | 44 | 0.210 |
Why?
| Genes, rRNA | 1 | 2023 | 39 | 0.210 |
Why?
| Cornea | 1 | 2023 | 102 | 0.210 |
Why?
| RNA, Viral | 4 | 2020 | 565 | 0.210 |
Why?
| Ophthalmic Solutions | 1 | 2023 | 66 | 0.210 |
Why?
| Optic Disk | 1 | 2023 | 38 | 0.210 |
Why?
| Dietary Proteins | 1 | 2023 | 122 | 0.210 |
Why?
| Metabolome | 2 | 2023 | 282 | 0.200 |
Why?
| Sex Hormone-Binding Globulin | 1 | 2022 | 48 | 0.200 |
Why?
| Alcohol Drinking | 2 | 2019 | 651 | 0.200 |
Why?
| Epidemiologic Studies | 1 | 2022 | 57 | 0.200 |
Why?
| Drug Users | 1 | 2022 | 41 | 0.200 |
Why?
| Cancellous Bone | 1 | 2021 | 20 | 0.190 |
Why?
| Pseudouridine | 1 | 2021 | 4 | 0.190 |
Why?
| Social Determinants of Health | 1 | 2024 | 135 | 0.190 |
Why?
| Hypotension | 1 | 2023 | 116 | 0.190 |
Why?
| Uridine | 1 | 2021 | 29 | 0.190 |
Why?
| DNA, Bacterial | 1 | 2023 | 311 | 0.190 |
Why?
| Diabetes Mellitus, Type 2 | 3 | 2021 | 2094 | 0.190 |
Why?
| Femur Neck | 1 | 2021 | 59 | 0.190 |
Why?
| Alpha-Globulins | 3 | 2017 | 19 | 0.190 |
Why?
| Odds Ratio | 4 | 2018 | 953 | 0.180 |
Why?
| Age Factors | 5 | 2020 | 2894 | 0.180 |
Why?
| Ascaris | 1 | 2020 | 2 | 0.180 |
Why?
| Visual Acuity | 1 | 2022 | 274 | 0.180 |
Why?
| RNA, Ribosomal, 16S | 1 | 2023 | 485 | 0.180 |
Why?
| North America | 3 | 2017 | 256 | 0.180 |
Why?
| Sex Factors | 4 | 2018 | 1715 | 0.180 |
Why?
| Sickness Impact Profile | 1 | 2020 | 50 | 0.180 |
Why?
| Disease Progression | 7 | 2023 | 2380 | 0.170 |
Why?
| Survival Analysis | 3 | 2018 | 1211 | 0.170 |
Why?
| Kidney Transplantation | 2 | 2017 | 541 | 0.170 |
Why?
| Inpatients | 1 | 2023 | 380 | 0.170 |
Why?
| Malnutrition | 1 | 2020 | 62 | 0.170 |
Why?
| Adenosine | 1 | 2021 | 203 | 0.170 |
Why?
| Follow-Up Studies | 5 | 2021 | 4411 | 0.170 |
Why?
| Multicenter Studies as Topic | 1 | 2020 | 248 | 0.160 |
Why?
| Serum Albumin | 2 | 2024 | 137 | 0.160 |
Why?
| Prognosis | 5 | 2018 | 3328 | 0.160 |
Why?
| Retinal Diseases | 1 | 2020 | 76 | 0.160 |
Why?
| Interleukin-18 | 5 | 2024 | 219 | 0.160 |
Why?
| Carotid Intima-Media Thickness | 1 | 2019 | 65 | 0.160 |
Why?
| Prediabetic State | 1 | 2021 | 219 | 0.150 |
Why?
| Machine Learning | 1 | 2022 | 316 | 0.150 |
Why?
| Retrospective Studies | 6 | 2023 | 12542 | 0.150 |
Why?
| Glucocorticoids | 1 | 2022 | 532 | 0.150 |
Why?
| Substance Abuse, Intravenous | 2 | 2017 | 99 | 0.150 |
Why?
| Cerebrovascular Disorders | 1 | 2019 | 82 | 0.150 |
Why?
| Epidemiologic Research Design | 1 | 2018 | 27 | 0.150 |
Why?
| Hand Strength | 2 | 2022 | 95 | 0.150 |
Why?
| Bisexuality | 1 | 2018 | 17 | 0.150 |
Why?
| Hyperglycemia | 1 | 2021 | 291 | 0.150 |
Why?
| Case-Control Studies | 6 | 2023 | 3003 | 0.150 |
Why?
| Coronary Artery Disease | 1 | 2023 | 607 | 0.150 |
Why?
| AIDS-Related Opportunistic Infections | 2 | 2016 | 116 | 0.140 |
Why?
| Tenofovir | 2 | 2016 | 204 | 0.140 |
Why?
| Hypercholesterolemia | 1 | 2018 | 90 | 0.140 |
Why?
| Cystatin C | 2 | 2016 | 62 | 0.140 |
Why?
| Acetylglucosaminidase | 2 | 2016 | 5 | 0.140 |
Why?
| Sustained Virologic Response | 1 | 2017 | 33 | 0.140 |
Why?
| Dihydroxycholecalciferols | 1 | 2016 | 1 | 0.140 |
Why?
| HIV Seropositivity | 2 | 2017 | 109 | 0.140 |
Why?
| Time Factors | 5 | 2018 | 6112 | 0.140 |
Why?
| Geriatric Assessment | 1 | 2018 | 176 | 0.140 |
Why?
| Young Adult | 9 | 2023 | 10455 | 0.140 |
Why?
| Albuminuria | 4 | 2023 | 164 | 0.140 |
Why?
| Acute-Phase Proteins | 2 | 2013 | 64 | 0.130 |
Why?
| Data Interpretation, Statistical | 1 | 2018 | 321 | 0.130 |
Why?
| Lipocalins | 2 | 2013 | 34 | 0.130 |
Why?
| HIV Wasting Syndrome | 1 | 2016 | 4 | 0.130 |
Why?
| Adolescent | 10 | 2023 | 17831 | 0.130 |
Why?
| Alzheimer Disease | 1 | 2021 | 442 | 0.130 |
Why?
| Inflammation | 3 | 2018 | 2477 | 0.130 |
Why?
| Hemoglobins | 2 | 2020 | 315 | 0.130 |
Why?
| Sleep Wake Disorders | 1 | 2018 | 233 | 0.120 |
Why?
| Geography | 1 | 2016 | 177 | 0.120 |
Why?
| Reproducibility of Results | 2 | 2023 | 2762 | 0.120 |
Why?
| Patient Care | 1 | 2016 | 101 | 0.120 |
Why?
| Continuity of Patient Care | 1 | 2017 | 253 | 0.120 |
Why?
| Arsenic | 1 | 2015 | 37 | 0.120 |
Why?
| Living Donors | 1 | 2017 | 270 | 0.120 |
Why?
| Immune Tolerance | 1 | 2017 | 323 | 0.120 |
Why?
| Apolipoproteins | 1 | 2014 | 36 | 0.120 |
Why?
| Lipoproteins, HDL | 1 | 2014 | 75 | 0.120 |
Why?
| Canada | 4 | 2017 | 322 | 0.120 |
Why?
| Factor Analysis, Statistical | 1 | 2015 | 257 | 0.110 |
Why?
| HIV Seronegativity | 1 | 2013 | 24 | 0.110 |
Why?
| Kidney Tubules, Proximal | 1 | 2014 | 113 | 0.110 |
Why?
| Graft Rejection | 1 | 2017 | 513 | 0.110 |
Why?
| Models, Theoretical | 1 | 2017 | 515 | 0.110 |
Why?
| Kidney Glomerulus | 1 | 2014 | 100 | 0.110 |
Why?
| Lipodystrophy | 1 | 2013 | 16 | 0.110 |
Why?
| beta 2-Microglobulin | 1 | 2013 | 45 | 0.110 |
Why?
| Reverse Transcriptase Inhibitors | 1 | 2013 | 82 | 0.100 |
Why?
| Proto-Oncogene Proteins | 2 | 2013 | 608 | 0.100 |
Why?
| Organophosphonates | 1 | 2013 | 90 | 0.100 |
Why?
| Cardiovascular Diseases | 1 | 2023 | 1727 | 0.100 |
Why?
| Patient Compliance | 1 | 2015 | 524 | 0.100 |
Why?
| Renal Dialysis | 1 | 2015 | 374 | 0.100 |
Why?
| Pneumocystis carinii | 1 | 2011 | 7 | 0.100 |
Why?
| Antibodies, Fungal | 1 | 2011 | 9 | 0.100 |
Why?
| Healthcare Disparities | 1 | 2017 | 479 | 0.100 |
Why?
| Pneumonia, Pneumocystis | 1 | 2011 | 24 | 0.090 |
Why?
| Adenine | 1 | 2013 | 219 | 0.090 |
Why?
| Dyslipidemias | 1 | 2013 | 154 | 0.090 |
Why?
| Patient Acceptance of Health Care | 1 | 2017 | 681 | 0.090 |
Why?
| Motor Activity | 1 | 2016 | 640 | 0.090 |
Why?
| Baltimore | 2 | 2021 | 43 | 0.090 |
Why?
| Fungal Proteins | 1 | 2011 | 119 | 0.090 |
Why?
| Risk Assessment | 3 | 2018 | 2967 | 0.090 |
Why?
| Medication Adherence | 1 | 2015 | 536 | 0.090 |
Why?
| Acute Kidney Injury | 1 | 2016 | 637 | 0.090 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 3 | 2016 | 35 | 0.090 |
Why?
| Predictive Value of Tests | 4 | 2016 | 1796 | 0.090 |
Why?
| Lipocalin-2 | 3 | 2016 | 61 | 0.080 |
Why?
| Severity of Illness Index | 2 | 2015 | 2537 | 0.080 |
Why?
| Health Services Accessibility | 1 | 2015 | 761 | 0.080 |
Why?
| Child | 7 | 2023 | 18404 | 0.080 |
Why?
| Surveys and Questionnaires | 1 | 2020 | 4620 | 0.080 |
Why?
| Homicide | 1 | 2008 | 53 | 0.080 |
Why?
| Proportional Hazards Models | 3 | 2017 | 1075 | 0.070 |
Why?
| Brain | 1 | 2019 | 2371 | 0.070 |
Why?
| Child, Preschool | 4 | 2023 | 9108 | 0.070 |
Why?
| Hepacivirus | 2 | 2022 | 229 | 0.070 |
Why?
| Membrane Glycoproteins | 3 | 2013 | 430 | 0.070 |
Why?
| Primary Health Care | 1 | 2015 | 1512 | 0.060 |
Why?
| Stroke | 1 | 2013 | 1021 | 0.060 |
Why?
| Treatment Outcome | 1 | 2018 | 9084 | 0.060 |
Why?
| Population Surveillance | 2 | 2017 | 392 | 0.060 |
Why?
| Diet, Protein-Restricted | 1 | 2023 | 10 | 0.060 |
Why?
| Research Design | 2 | 2021 | 928 | 0.050 |
Why?
| Neoplasms | 1 | 2017 | 2097 | 0.050 |
Why?
| Meibomian Glands | 1 | 2022 | 7 | 0.050 |
Why?
| Receptors, Virus | 2 | 2013 | 75 | 0.050 |
Why?
| Lubricant Eye Drops | 1 | 2022 | 4 | 0.050 |
Why?
| Loteprednol Etabonate | 1 | 2022 | 6 | 0.050 |
Why?
| Constriction, Pathologic | 1 | 2023 | 208 | 0.050 |
Why?
| Chi-Square Distribution | 2 | 2014 | 493 | 0.050 |
Why?
| Intelligence | 1 | 2023 | 130 | 0.050 |
Why?
| Tobramycin | 1 | 2022 | 47 | 0.050 |
Why?
| Infant | 3 | 2023 | 7959 | 0.050 |
Why?
| Retinal Ganglion Cells | 1 | 2023 | 92 | 0.050 |
Why?
| Cyclosporine | 1 | 2022 | 161 | 0.050 |
Why?
| Support Vector Machine | 1 | 2022 | 34 | 0.050 |
Why?
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 29 | 0.050 |
Why?
| Sugar Acids | 1 | 2021 | 4 | 0.050 |
Why?
| Citrates | 1 | 2021 | 43 | 0.050 |
Why?
| Linear Models | 2 | 2014 | 768 | 0.050 |
Why?
| Memory, Short-Term | 1 | 2023 | 225 | 0.050 |
Why?
| Alanine | 1 | 2021 | 104 | 0.050 |
Why?
| Renal Replacement Therapy | 1 | 2021 | 66 | 0.050 |
Why?
| Eating | 1 | 2023 | 344 | 0.050 |
Why?
| Hearing | 1 | 2022 | 134 | 0.050 |
Why?
| Meta-Analysis as Topic | 1 | 2021 | 158 | 0.050 |
Why?
| Metabolic Networks and Pathways | 1 | 2022 | 168 | 0.050 |
Why?
| Sulfides | 1 | 2021 | 94 | 0.050 |
Why?
| Los Angeles | 1 | 2020 | 56 | 0.040 |
Why?
| Tryptophan | 1 | 2021 | 136 | 0.040 |
Why?
| Audiometry, Pure-Tone | 1 | 2020 | 23 | 0.040 |
Why?
| Cataract | 1 | 2022 | 185 | 0.040 |
Why?
| Frailty | 1 | 2022 | 115 | 0.040 |
Why?
| Hydrocortisone | 1 | 2021 | 267 | 0.040 |
Why?
| Microcirculation | 1 | 2020 | 135 | 0.040 |
Why?
| Blood Glucose | 2 | 2021 | 1819 | 0.040 |
Why?
| Adrenal Cortex Hormones | 1 | 2022 | 497 | 0.040 |
Why?
| Genotype | 2 | 2014 | 1760 | 0.040 |
Why?
| Bayes Theorem | 1 | 2020 | 329 | 0.040 |
Why?
| Heterosexuality | 1 | 2018 | 29 | 0.040 |
Why?
| Diabetic Retinopathy | 1 | 2020 | 149 | 0.040 |
Why?
| Multimorbidity | 1 | 2018 | 33 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2022 | 1214 | 0.040 |
Why?
| Glucose | 1 | 2022 | 896 | 0.030 |
Why?
| Logistic Models | 1 | 2022 | 1840 | 0.030 |
Why?
| Blood Pressure | 1 | 2023 | 1538 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2020 | 1077 | 0.030 |
Why?
| Diet | 1 | 2023 | 1080 | 0.030 |
Why?
| History, 21st Century | 1 | 2017 | 159 | 0.030 |
Why?
| Nephrectomy | 1 | 2017 | 150 | 0.030 |
Why?
| Patient Outcome Assessment | 1 | 2017 | 122 | 0.030 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2016 | 60 | 0.030 |
Why?
| Ultrasonography | 1 | 2019 | 633 | 0.030 |
Why?
| Confidence Intervals | 1 | 2016 | 305 | 0.030 |
Why?
| Demography | 1 | 2016 | 260 | 0.030 |
Why?
| Apolipoprotein L1 | 1 | 2014 | 12 | 0.030 |
Why?
| Graft Survival | 1 | 2017 | 446 | 0.030 |
Why?
| Pandemics | 1 | 2022 | 1317 | 0.030 |
Why?
| Risk | 1 | 2017 | 812 | 0.030 |
Why?
| Nutrition Surveys | 1 | 2015 | 224 | 0.030 |
Why?
| Proteinuria | 1 | 2014 | 77 | 0.030 |
Why?
| Cooperative Behavior | 1 | 2016 | 381 | 0.030 |
Why?
| Sex Characteristics | 1 | 2018 | 640 | 0.030 |
Why?
| Health | 1 | 2014 | 74 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 1124 | 0.030 |
Why?
| Diagnostic Errors | 1 | 2014 | 149 | 0.030 |
Why?
| Drug Monitoring | 1 | 2014 | 184 | 0.030 |
Why?
| Health Policy | 1 | 2016 | 334 | 0.030 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 140 | 0.030 |
Why?
| Absorptiometry, Photon | 1 | 2013 | 224 | 0.030 |
Why?
| Cholesterol, HDL | 1 | 2013 | 183 | 0.030 |
Why?
| Alleles | 1 | 2014 | 789 | 0.020 |
Why?
| Cholesterol, LDL | 1 | 2013 | 307 | 0.020 |
Why?
| Cholesterol | 1 | 2013 | 367 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2013 | 362 | 0.020 |
Why?
| Animals | 2 | 2023 | 31694 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2014 | 1430 | 0.020 |
Why?
| Triglycerides | 1 | 2013 | 467 | 0.020 |
Why?
| Serine Endopeptidases | 1 | 2011 | 102 | 0.020 |
Why?
| Immunoglobulin M | 1 | 2011 | 246 | 0.020 |
Why?
| Adipose Tissue | 1 | 2013 | 539 | 0.020 |
Why?
| Interleukin-6 | 1 | 2013 | 676 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 797 | 0.020 |
Why?
| Social Problems | 1 | 2008 | 11 | 0.020 |
Why?
| Tanzania | 1 | 2008 | 41 | 0.020 |
Why?
| Age Distribution | 1 | 2008 | 342 | 0.020 |
Why?
| Sex Distribution | 1 | 2008 | 337 | 0.020 |
Why?
| Chronic Disease | 1 | 2013 | 1578 | 0.020 |
Why?
| Immunoglobulin G | 1 | 2011 | 770 | 0.020 |
Why?
| Cause of Death | 1 | 2008 | 361 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2014 | 2084 | 0.020 |
Why?
| Insulin Resistance | 1 | 2013 | 1072 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2013 | 2279 | 0.010 |
Why?
|
|
Abraham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|